Bicara Therapeutics (BCAX) Cash & Equivalents (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Cash & Equivalents of $323.5 million for Q1 2026, down 30.0% year-over-year from $462.1 million in Q1 2025, and up 234.55% quarter-over-quarter from $96.7 million in Q4 2025.
Bicara Therapeutics (BCAX) Cash & Equivalents (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Cash & Equivalents history runs 4 years deep, the most recent figure standing at $323.5 million for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 30.0% year-over-year to $323.5 million; the TTM figure through Mar 2026 stood at $323.5 million (down 30.0% YoY), while the FY2025 annual figure was $96.7 million, down 80.26% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $323.5 million, up from $96.7 million in the prior quarter.
- The five-year high for Cash & Equivalents was $520.8 million in Q3 2024, with the low at $96.7 million in Q4 2025.
- The 4-year median for Cash & Equivalents is $380.0 million (2025), against an average of $341.4 million.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 112.51% in 2024, then plunged 80.26% in 2025.
- Bicara Therapeutics' Cash & Equivalents stood at $230.4 million in 2023, then surged by 112.51% to $489.7 million in 2024, then slumped by 80.26% to $96.7 million in 2025, then jumped by 234.55% to $323.5 million in 2026.
- Business Quant data shows BCAX's Cash & Equivalents at $323.5 million in Q1 2026, $96.7 million in Q4 2025, and $171.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 96.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 96.60 Mn |
| Mar 31, 2026 | 323.46 Mn |
| Dec 31, 2025 | 96.69 Mn |
| Sep 30, 2025 | 171.67 Mn |
| Jun 30, 2025 | 436.60 Mn |
| Mar 31, 2025 | 462.10 Mn |
| Dec 31, 2024 | 489.71 Mn |
| Sep 30, 2024 | 520.80 Mn |
| Dec 31, 2023 | 230.44 Mn |